Feature Paper in Virology

Dear Colleagues,

The year 2024 has been a rich one for virology, with discoveries that promise to transform our understanding of and fight against viruses. Thanks to technological advances (next-generation sequencing, IA, RNA vaccines) and unprecedented international collaborations, promising prospects are opening up for personalized medicine, in response to current or future epidemics, as well as for the treatment of chronic diseases of viral origin.

1. New antiviral therapies:

In 2024, new classes of antiviral drugs capable of targeting specific structures of viruses were developed, making their reproduction impossible. These innovative treatments have shown promising efficacy against major pathogens such as HIV, hepatitis B and various coronaviruses. Preliminary clinical trials have revealed impressive success rates, paving the way for more effective, less toxic treatments.

2. Next-generation mRNA vaccines:

Inspired by the success of mRNA vaccines against COVID-19, this technology has been extended to design vaccines capable of preventing a variety of viral diseases. In 2024, trials of mRNA vaccines against influenza and Ebola began, showing promising results. These vaccines can be adapted to respond to future epidemics.

3. Understanding Host-Virus Interactions:

Advances in molecular biology and genomics have led to a better understanding of how viruses interact with their hosts. In 2024, mechanisms were identified by which viruses manipulate host cells for their own benefit. These discoveries could lead to new therapeutic strategies that exploit these interactions, helping to boost the host's immune response.

4. Surveillance and early detection:

With viral epidemics on the rise, upstream surveillance has become crucial. In 2024, the development of artificial intelligence-based detection systems made it possible to track viral threats in real time. These innovative tools analyze huge masses of data from a variety of sources, enabling rapid identification of outbreaks and a coordinated response from health authorities.

5. Awareness and Education:

The virology breakthroughs of 2024 were not only technical, but also social and educational programs have been launched to raise public awareness of viruses and their prevention. These initiatives aim to promote vaccination and inform about hygiene measures, thus helping to reduce the speed at which viral diseases spread.

The year 2024 was marked by groundbreaking discoveries in virology, opening up new perspectives for public health through technological innovation, international collaboration and awareness-raising.

Dr. Isabelle Chemin
Collection Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• new antiviral therapies
• mRNA vaccines
• host-virus interactions
• viral detection